Core Viewpoint - Huiyu Pharmaceutical (688553.SH) expects a net loss attributable to shareholders of the parent company for the fiscal year 2025, ranging from a loss of 29 million yuan to a loss of 24 million yuan, representing a year-on-year decline of 108.91% to 107.38% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be between 78 million yuan and 93 million yuan for 2025, which indicates a year-on-year change of a decline of 15.33% to an increase of 0.96% compared to the previous year [1] Investment Impact - The company's invested enterprise, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., is set to be listed on the Hong Kong Stock Exchange under the 18A listing standard on August 20, 2024, with the stock code 02410.HK [1] - The fair value change loss of 173 million yuan during the reporting period was influenced by the stock price fluctuations of the invested enterprise [1]